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Serial assessment of glomerular filtration rate in lupus nephropathy. In
patients with lupus nephropathy (LN), previous studies have shown
that creatinine clearance (Car) overestimates true glomerular ifitration
rate as measured by inulin clearance (C1,), and that among patients the
degree of overestimation is highly variable. We sought to determine
whether the discrepancy between C. and Cli, remains constant over
time (months, years) in each individual patient, and therefore whether
serial measurements of Cc,. reliably reflect the direction and magnitude
of change in C1,,. Twenty-five patients with LN underwent simultaneous
determinations of Ce,. and C1,, performed two to four (mean 3.3) times
over three years. In a given patient, it was found that the ratio of C/
C1,, changed substantially over time (mean SD 0.16 with 95% confidence
interval of 0.12 to 0.20). Thus, in about 32% of cases the ratio of Cr/Cin
will vary more than 16% from a previously measured value of C,i
Ci,,. Patients with both high and low values of C1,, showed similar
variability in CCrJCIn over time. Variability in Ccr/Cin was found
regardless of whether Cm was increasing, decreasing, or constant over
time. In nearly one-half of all measurements of Ce,., the corresponding
change in C1,, was directionally discordant. lothalamate and techne-
tium-DTPA renal clearances correlated highly with Ci,, (R2 = 0.99). We
conclude that the discrepancy between Ce,. and C1,, can vary greatly
over time in an individual patient. Consequently, serial Cc. does not
accurately measure the direction or magnitude of change in glomerular
filtration rate in lupus nephropathy.
Creatinine clearance (Car) substantially overestimates inulin
clearance (C1,,), the accepted standard for glomerular filtration
rate (GFR), in the majority of patients with lupus nephropathy
(LN) [1—3]. However, serial trends in creatinine (Cr) or Ce,. are
commonly used in the clinical practice and research setting to
measure changes in GFR [4—6]. This would be acceptable for
most purposes if the discrepancy ratio CCIJCIn remained con-
stant over time in any given lupus patient or if it were a
predictable function of easily measured variables. It might, for
example, be possible to better predict C1,, from Cr given
knowledge of the patient's past Cr/Cin ratio.
We serially studied 25 patients with LN over a three year
period to determine whether the discrepancy ratio CcJCIT,
remained constant in this selected population and whether
subsequent Ci,, could be predicted from knowledge of the past
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Cc,JCjn ratio and Car. We compared Cr, inpatient Ce,., 24-hour
outpatient creatinine clearance (24 Ce,.), and BUN as alterna-
tive estimates of GFR available to the clinician.
Methods
Patient selection
Twenty-nine nonpregnant female patients from the UCSF
Rheumatology Clinic population were initially studied. All met
four or more of the American Rheumatism Association criteria
for systemic lupus erythematosus and met at least one of the
following criteria for lupus nephropathy: 1) red blood cell casts;
2) proteinuria, 2+ by dipstick or >600 mg in a 24-hour urine
collection; 3) hematuria, 2+ by dipstick or 20 RBCs per
high-power field; 4) serum creatinine level >1.5 mgldl; 5)
creatinine clearance <80 cc/mm; or 6) increase in serum creat-
mine level of 30% over two months. Twenty-five of these
patients consented to be serially studied. Five patients were
studied twice, seven patients were studied three times, and
thirteen patients were studied four times from 1984 to 1986.
Clinical and laboratory parameters
On admission to the General Clinical Research Center, data
on clinical history (blood pressure, pulse, peripheral edema,
protein intake), drug use (nonsteroidal anti-inflammatory drugs
including aspirin, acetaminophen, antihypertensive drugs,
prednisone, immunosuppressive drugs and cimetidine), a lupus
activity index (designed to quantitate the physician's assess-
ment of activity, symptoms, signs, laboratory tests, prednisone
and immunosuppressive drug use), and laboratory data (HCT,
WBC, serum K+, BUN, serum albumin, CHSO, anti-ds-DNA,
urinalysis, 24-hour urine for creatinine clearance and total
protein) were recorded on each patient.
Renal clearance studies
After an overnight fast, the patients had a Foley catheter
inserted and ingested 700 cc of water over sixty minutes.
Subsequently, at thirty minute intervals for approximately four
hours, the patients ingested 240 cc of water. A priming dose of
10% inulin (0.5 ml/kg body wt); (American Critical Care,
McGraw Park, Illinois, USA), and, in one phase of the study,
600 mglml iothalamate (0.1063 mI/kg body weight; Conray 60,
Mallinkrodt, Inc., Paris, Kentucky, USA) were given over five
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minutes. In the third and fourth phases of the study, a bolus of
0.5 mC of technetium-DTPA was given with the inulin. Sustain-
ing infusions of inulin and iothalamate (but not technetium-
DTPA) were begun at a rate estimated to maintain a serum
concentration of 25 mg/100 ml of inulin and 15 mg/100 ml of
iothalamate. After an equilibration period of 45 minutes follow-
ing injection of the priming solution, six 30-minute urine sam-
ples, with blood samples at each midpoint, were collected.
Renal clearances of creatinine, inulin, iothalamate, and techne-
tium-DTPA were calculated, using the standard formula, (U x
V)/P. All data are presented as the mean of six clearance
periods per study per patient.
Measurements
Creatinine was measured by a modified Jaffe reaction per-
formed on a Beckman Astra-8 autoanalyzer (Beckman Instru-
ments, Fullerton, California, USA) [7]. The modified Jaffe
creatinine measurement is the standard measure for clinical use
and has been used in past studies comparing creatinine and
inulin clearances [2, 8]. For the inulin assay, plasma protein was
removed by precipitation. The urine and plasma inulin concen-
trations were assessed by hydrolysis of inulin to fructose. The
anthrone derivative of fructose was colorimetrically quantified
on an autoanalyzer [9]. lothalamate was quantified by fluores-
cence excitation [10]. Technetium-DTPA was counted for two
minutes on a gamma counter, with grouping of the correspond-
ing blood and urine samples.
Results
Patient characteristics
Twenty-five female patients aged 18 to 58 (mean 32.4 10.8)
participated in the serial study. The average weight was 58.2
10.3 kg. Body surface area varied from 1.34 to 1.85 (mean =
1.59 0.13). Fifteen patients had a history of hypertension.
Nine had peripheral edema at some point during the study. Five
were taking aspirin, while five were taking a nonsteroidal
anti-inflammatory agent. All were taking prednisone at some
point during the study, in doses varying from 2 to 60 mg. Nine
were taking chlorambucil. Only one patient took cimetidine.
Fifteen patients took a diuretic. Twelve patients took a beta-
blocking antihypertensive. Five patients required a third-line
antihypertensive drug (alphamethyl dopa, clonidine, hydral-
azine, or prazosin). One patient was on a calcium channel
blocker. The lupus activity index (0 to 3 scale) varied from 0.17
to 2.40.
Nine patients had nephrotic syndrome during the study, with
less than 3 grams proteinuria per day. Serum creatinine levels
varied from 0.6 to 2.0 mgldl. Twenty-four-hour creatinine
clearance (24 Car) varied from 24.3 to 203.7 cc/mm.
Change in CC,JCJ over ti,ne
Table 1 shows the individual values (by subject and by study)
for C1, Car, and Ccr/Cin arranged in descending order of initial
study C1,,, with mean SD for each patient. The serial mean
Ccr/Cin was 1.30 0.16. In 13 of the 25 patients C. overesti-
mated C1,, by 30% or more. Three patients had no overall
discrepancy (Patient #12, serial mean C1JC1,, = 1.04 0.13;
Patient #25, 1.07 0.08; and Patient #9, 1.03 0.17).
However, these patients did not appear to differ in any definable
way from the other lupus patients in the study. Patient #12 was
on widely varying doses of prednisone (20 mg, 40 mg, 15 mg)
during the study, her lupus activity index decreased from 1.8 to
0.9, her albumin improved from 2.7 to 3.6 mg/dl, her anti-DNA
level dropped from 47.5 to 13.1 (normal, <2.5), and her
proteinuria varied slightly (2.3, 2.7, 2.0 grams per day). Patient
#25 was also on varying doses of prednisone (15 mg, 35 mg),
with a changing lupus activity index (0.36, 0.74), constant
serum albumin (4.1 mg/dl), constant anti-DNA level (21.6), and
minimal proteinuria (0.08 to 0.10 grams per day). Patient #9
was on low doses of prednisone (6mg, 3.5 mg, and 2.5 mg), had
low lupus activity (0.7 to 0.8), a slight drop in serum albumin
(4.4 to 3.7 mgldl), a slight rise in anti-DNA (12.4, 16.0, 19.2) and
constant proteinuria (0.5 grams per day). None of these three
patients (#12, #25, #9) were taking diuretics.
The overestimation of C1,, by Ce,. was sufficient to mask the
existence of renal insufficiency in some patients. In six patients
(#14, #24, #10, #5, #2, #7), an abnormal C1 was found with
a normal Cr (greater than 80 mi/mm). In our patients, serum
creatinine did not rise above 1.0 mg/dl, and Ce,. did not fall
below 80 ml/min, until C1 was 51 mllmin or less. Two patients
(#7 and #10) whose serum creatinine levels were 0.6 and 0.7
mgldl, respectively, had reductions of C1,, of 50% or more from
normal. Patient #21, who had a normal serum creatinine and
urinalysis, had a C1,, of only 37.7 ml/min, in the range of severe
renal insufficiency.
The intra-patient variation in CCrJCIfl is represented by the
standard deviation calculated for each patient. The average of
these standard deviations was 0.16 (95% confidence interval
0.12 to 0.20). Because one standard deviation subtends about
68% of a population, in 32% of cases the ratio C,iC1,, will vary
more than 16% from a previously measured value of CcJCin.
Another measure of intra-patient variability is given by the
range, that is, the maximum CC,JCJ,, minus the minimum CJ
C1,,. The mean of these was 0.34 (95% confidence interval 0.22
to 0.46). The degree of intra-patient variability in CCr/CIn 5
depicted graphically in Figure 1, which shows the relationship
between subsequent values of the ratio CCr/CIfl (studies 2, 3, 4)
and the initial value (study 1) in each of the 25 patients.
The variability of C,JC1,, over time occurred at all levels of
C1,,. For example, the standard deviation of the serial mean Ci
C1 for the four patients with the highest initial C1,, was 0.11 to
0.37 (% coefficient of variation, %COV, 8.4 to 27.1), and for the
four patients with the lowest Ci,, was 0.15 to 0.37 (%COV, 13.0
to 23.6).
The variability of C,JC1,, over time occurred regardless of
whether Cth was increasing, decreasing, or constant. For ex-
ample, in the five patients (#17, #10, #4, #3, #1) whose
standard deviation was greater than 0.30, we found that, in
three, C1,, was increasing (#10, #3, #1), in one C1,, was
decreasing (#17), and in one (#4), C1 was virtually constant.
Given that the itself poorly approximates the C1,,, Table
2 compares several methods of approximating C1,,. The formula
combined in various ways several inpatient and outpatient
variables available to us, Thus, each formula (or model) in
Table 2 represents a way of estimating or predicting C1,, in terms
of other measurable values. The quality of each formula as an
estimator of C1 is given by the standard deviation of the
percent difference between the observed C11, and the values
predicted by the various models (or formulas). The correlation
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Table 1. Summary of serial measurements of inulin and creatinine clearance in 25 patients with lupus nephropathy
C1,,
mi/mm
Ccr
mi/mm C1,/C1,,
Study Study Study Study Study Study Study Study Study Study Study Study
Pt# #1 #2 #3 #4 %COV #1 #2 #3 #4 %COV #1 #2 #3 #4 Mean SD %COV
11 123.4 144.0 103.3 16.5 173.4 170.9 134.7 13.6 1.41 1.19 1.30 1.30 0.11 8.4
17 109.0 104.4 91.9 8.7 142.6 109,0 163.8 20.0 1.31 1.04 1.78 1.38 0.37 27.1
13 104.3 96.9 86.2 85.7 9.6 124.9 109.9 127.3 122.5 6.4 1.20 1.13 1.48 1.43 1.31 0.17 12.9
12 104.1 126.1 140.4 101.9 15.6 122.6 113.1 136.9 113.0 9.3 1.18 0.90 0.98 1.11 1.04 0.13 12.2
22 100.3 103.9 2.5 110.4 120.6 6.2 1.10 1.16 1.13 0.04 3.8
18 95.1 78.2 92.0 94.2 8.8 109.9 95.7 101.5 129.0 13.3 1.16 1.22 1.10 1.37 1.21 0.12 9.5
25 88.3 107.6 13.9 99.7 109.8 6.8 1.13 1.02 1.07 0.08 7.1
15 85.3 83.0 85.3 90.8 3.9 116.9 106.9 103.3 102.7 6.1 1.37 1.29 1.21 1.13 1.25 0.10 8.2
20 84.4 86.2 1.5 106.5 100.4 4.2 1.26 1.16 1.21 0.07 5.7
6 81.2 88.1 79.8 69.6 9.6 96.3 126.2 77.7 74.4 25.4 1.19 1.43 0.97 1.07 1,17 0.20 17.0
9 79.7 100.9 91.5 98.3 10.2 101.2 87.6 92.7 96.9 6.1 1.27 0.87 1.01 0.99 1.03 0.17 16.4
14 66.5 55.1 49.7 63.0 13.0 88.0 76.1 61.2 68.0 15.7 1.32 1.38 1.23 1.08 1.25 0.13 10.5
24 58.2 66.4 9.3 74.8 81.1 5.7 1.29 1.22 1.25 0.05 3.6
16 51.4 57.4 44.8 12.3 76.0 72.6 64.0 8.7 1.48 1.26 1.43 1.39 0.11 8.0
10 50.5 68.3 73.7 18.9 95.1 86.6 106.9 10.6 1.88 1.27 1.45 1.53 0.32 20.6
5 50.2 56.5 53.9 57.3 5.9 73.3 82.4 81.4 87.0 7.0 1.46 1.46 1.51 1.52 1.49 0.03 2.1
2 47.8 54.4 68.1 78.0 21.9 75.4 88.2 89.0 113.3 17.3 1.58 1.62 1.31 1.45 1.49 0.14 9.5
7 45.5 64.2 24.1 67.5 87.7 18.4 1.48 1.37 1.42 0.08 5.8
19 39.7 43.4 47.5 9.0 61.1 59.8 64.4 3.8 1.54 1.38 1.36 1.42 0.10 7.0
4 39.2 37.4 43.6 8.0 37.9 47.3 68.3 30.4 0.97 1.26 1.57 1.27 0.30 23.7
3 38.9 86.9 88.3 99.8 34.4 67.9 128.3 87.0 118.1 27.8 1.75 1.48 0.99 1.18 1.35 0.33 24.7
21 37.7 42.6 46.4 45.5 9.1 49.4 41.6 52.4 45.8 9.9 1.31 0.98 1.13 1.01 1.11 0.15 13.7
1 35.8 46.4 48.7 49.1 13.9 75.5 65.7 62.1 72.3 8.9 2.11 1.42 1.28 1.47 1.57 0.37 23.6
23 29.8 30.3 37.0 12.4 52.4 41.0 51.1 13.0 1.76 1.35 1.38 1.50 0.23 15.1
8 23.4 22.7 25.1 27.9 9,3 36.1 30.6 36.1 31.4 8.8 1.54 1.35 1.44 1.13 1.36 0.18 13.0
Mean 66.8 74.1 69.9 73.9 12.1 89.4 89.6 88.1 90.3 12.1 1.40 1.25 1.29 1.23 1.30 0.16 12.4
Patients are listed in descending order of C1,, (Study #1). To permit inter-patient comparisons of degree of C1,, variability overtime, the Table
lists for each patient the C1,, coefficient of variation (%COV), expressing the standard deviation from the mean of the serial C1,, values (from Study
#1 to the patient's final study) as a percent of the mean. Likewise, the Table lists for each %COV values for C1 and C,iC1,,, and the serial mean
and standard deviation (SD) for CQJCIII. Note that patients with higher values of C1,, also showed variability in Cc1JC1,, over time. Note that the
directional change in CC1,, over time frequently differed from the directional change in C1,,.
coefficient (R) between the observed Cth and the formula
generated values affords another measure of the quality of the
formula as an approximator of observed Ci,.. A value of 1.00 for
R2 represents a perfect correlation, whereas a value of 0.00
indicates no correlation. The rationale for taking this approach
is that all methods of estimating C1,. can be compared.
Inpatient estimates of C1,,
Table 2 contains three estimates of C1,. that required an
inpatient study. The first model was generated using a multiple
linear regression equation. The C1,, and 24-hour protein ob-
tained from the patient's first study combined with the subse-
quent 24-hour protein were used to estimate the subsequent
C1,,. This computer-generated model had a SD of 0.16 and R2 of
0.83. The second formula was also generated by multiple linear
regression using the Cr (simultaneous inpatient creatinine
clearance) to estimate C1,,. This model, which had a SD of 0.19
and an R2 of 0.81, represented the ability of Cr alone to
estimate C1,.. The third inpatient estimate was the intuitively
obvious one obtained by multiplying a previously measured
ratio of C1,, to Ce,., by the currently measured Car. If there were
little intra-patient variation in C1,,/C,, then this would be an
accurate estimate of C1,,. It gave a SD of 0.19 and an R2 of 0.76.
Figure 2 depicts the data from this model, graphically showing
the difference between the observed value and the value pre-
dicted assuming constancy of Cc,JC1,,. Note that assuming
constancy of CC,JCI,. can, in a given patient, result in an
underestimation or overestimation of GFR by as much as 30 to
40 mI/mm. As can be seen from the 95% confidence intervals in
Table 2, the three inpatient models were not significantly
different as estimators of C1,.
Outpatient estimates of Gin
Table 2 contains three estimates of C1,, utilizing outpatient
data. All were created with multiple linear regression. First we
examined the inverse creatinine. It is used instead of creatinine
itself because it should be proportional to GFR in the absence of
changes in muscle mass, and therefore should be proportional
to C1,. This model gave a SD of 0.28 and an R2 of 0.59.
Secondly, the 24 Ce,. (outpatient 24-hour creatinine clearance)
was used to estimate C1,., with a SD of 0.30 and an R2 of 0.52.
Finally 1/BUN was evaluated as an estimate of C, with a SD of
0.35 and an R2 of 0.39. It is of note that the cheaper and
easier-to-obtain 1/Cr was an equivalent or better estimate of C5,1
than the 24 Car. The addition of other outpatient variables
(including the urine protein measurement by dipstick or by
24-hour urine) did not add significantly to the predictive power
of these models.
Alternative measures of GFR
We compared the regression models for two alternative
measures of GFR, iothalamate (C10) and technetium-DTPA
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Fig. 1. Relationship between subsequent
values of the ratio C,iC1, (studies 2,3,4;
vertical scale) and the initial value of the ratio
(study 1; horizontal scale) during serial
measurements over three years in patients
with lupus nephropathy. For any given value
of C,/C1,, in study 1, the diagonal line of
identity gives the subsequent value of CC,JCIfl
if the ratio is unchanged. Note that for any
given value of C/C1,, in study 1, subsequent
measured values are unpredictably higher or
lower. Thus, the value of C0/C1,, measured in
a single study is not sufficient for predicting
subsequent values of inulin clearance from
2.1 subsequent measurement of creatinine
clearance only. Symbols are: (U) study 2; (+)
study 3; () study 4.
Table 2. Comparison of methods of estimating inulin clearance
95% Confidence
interval
Incorporated variables Formula 5D for SD R2
Inpatient models
U24, past C1,,, past U24 0.9 (past C10) + 3.8 (past U24) — 3.7 (U24) 0.16 0.20—0.13 0.83
Cc, —1.6 + 0.8 (Ccr) 0.19 0.22—0.16 0.81
C, past Ccr/Cin past Cin/Cr x Ccr 0.19 0.24-0.16 0.76
Outpatient models
1/Cr —9.3 + 68 (I/Cr) 0.28 0.33—0.25 0.59
24 Ce,. 28.2 + 0,5 (24 Ccr) 0.30 0.3541.26 0.52
1/BUN 28.5 + 760.7 (1/BUN) 0.35 0.41—0.31 0.39
Alternative renal clearances
C10 —2.1 + 0.9 (C10) 0.06 0.09—0.05 0.99
CDTPA 4.4 + I (Cr,) 0.09 0.120.08 0.93
The table contains the variables incorporated in the predictive models for inulin clearance (C10), the regression equation or direct formula used,
the standard deviation (with 95% confidence intervals), and R2 for the per cent difference between the predicted C1,, and observed C1,, for each
model. All of the models except "past Cin/Ccr x Ccr" were constructed using multiple linear regression. Abbreviations are: U24, total protein in
24-hour urine collection; C1,,, inulin clearance; Cr, inpatient creatinine clearance done simultaneously with C10; Cr, serum creatinine; 24 Car,
24-hour outpatient creatinine clearance; BUN, blood urea nitrogen; C10, iothalamate clearance; CDTPA, technetium-DTPA clearance.
(CDTPA) renal clearances, in Table 2. Both gave excellent
estimates of inulin clearance, although C5,, was a slightly better
predictor than CDTPA (SD 0.06 vs. 0.09, R2 0.99 vs. 0.93). Figure
3 shows the regression lines for C1,, and CDTPA versus C5,,. The
regression line for C1,, slightly overestimates and that for CDTPA
slightly underestimates C50.
Relative change in renal parameters
We wished to determine how often serial C. would not
correctly identify the direction of change of C1,, (GFR). Figure
4 shows the relationship between the change in C1,, and the
corresponding change in Car. Note that for nearly one-half of all
serial measurements of Ce,., the corresponding changes in C1,,
were directionally discordant, that is, increasing or remaining
unchanged when Cr decreased, and decreasing or remaining
unchanged when Ce,. increased.
Twenty-two of the studies shown in Figure 4 involved a
change in C1 of 10 ml/min or more. C5,, increased by 10 cc/mm
or more in 14 studies in 11 patients. The Cr and 24 C,
decreased or did not change in 5 of these 14 studies (46%). The
inverse creatinine (1/Cr) decreased or remained the same in 8 of
the 14 studies (57%). C1,, decreased by 10 cc/mm or more in
eight studies on eight patients. The Cr increased or was
unchanged in two of the eight studies (25%). The inverse
0.7 0.9 1.1 1.3 1.5 1.7 1.9
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Fig. 2. Djfference between predicted and
observed values of inulin clearance in serial
measurements made over a three-year period
in patients with lupus nephropathy. The
values of inulin clearance are those predicted
from the measured value of creatinine
clearance for that study of that patient based
on the assumption that for a given patient the
ratio CC,JCI,, remains constant in serial studies
and is equal to the value of the ratio
determined in study 1, Patient numbers are
arranged left-to-right in descending order of
values of CC,JC in study 1. Patient numbers
are arranged left-to-right in descending Order
of values of C1,iC, in study 1. Data points
below the horizontal zero line indicate that
the observed value of inulin clearance
underestimates the predicted value, and vice-
versa for data points above the horizontal
zero line. Symbols are: (U) study 2; (+) study
3; (Q) study 4.
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creatinine and 24 Crincreased or stayed the same in five of the
eight studies (63%). Thus. in the 22 studies with an important
change in C1 (GFR), the direction of change was not correctly
identified by Cr (in 32%), 24 Ce,. (in 45%), or serum creatinine
(in 59%).
Patient example
An individual patient example that demonstrates the lack of
concordance between 24 Car, Ccr, and C1, is shown in Figure 5.
Patient EC (Fig. 5) had an outpatient 24 Cr that increased
from 58 to 103 cc/mm, although her inpatient Cr initially
decreased and then levelled off at 72 cc/mm. Neither of these
measurements reflects the trend in C1,, where there was initially
a small improvement, followed by a levelling off to 49 cc/mm.
The 24 C and Cr were misleading both in terms of the actual
level of renal function (greatly overestimating the GFR, as
reflected by C1) and in the direction of change in renal function.
Clinical or laboratory correlates
Multiple linear regression analysis failed to find any associa-
tion betwçen the lupus activity index and the discrepancy ratio
C,JC1. We examined, using multiple linear regression,
Fig. 4. Relationship between the change in
inulin clearance (relative to study I; vertical
scale) and the corresponding change in
creatinine clearance (relative to study 1;
horizontal scale) during serial measurements
over three years in patients with lupus
nephropathy. Note that for nearly one-half of
all serial measurements of creatinine
clearance, the corresponding changes in inulin
clearance were directionally discordant, that
—40 —20 0 20 40 60 80 is, increasing or remaining unchanged when
creatinine clearance decreased (filled squares),
and decreasing or remaining unchanged when
creatinine clearance increased (open squares).
Creatinine clearance, mi/mm
Change relative to study 1
whether any of the following drug therapies, prednisone, aspi-
rin, aspirin and/or nonsteroidal anti-inflammatory drug, chlo-
rambucil, cimetidine, diuretic drug, beta blocking drug, or
second-line antihypertensive drug (aiphamethyl dopa, cloni-
dine, hydralazine, prazosin) were associated with the discrep-
ancy ratio, C/C1. Both prednisone (P = 0.02) and diuretic
drug (P = 0.04) use were found to be associated with
Discussion
Creatinine clearance (Car) is known to substantially overes-
timate inulin clearance (C1), the standard measure of glomer-
ular filtration rate (GFR) in patients with renal insufficiency [2,
4, 8]. We and others have shown that the mean overestimation
is 40% or more in the well-defined group of patients with lupus
nephropathy (LN) [1—3]. In the present study, the serial mean
CJC1,, was 1.30. The overestimation was sufficiently large in
some patients to mask a moderate to large reduction in C1.
While this overestimation is scientifically heuristic, it would be
of little clinical importance if it were consistent. However, it is
known that the overestimation between patients is highly vari-
able [2, 4, 8]. The present study shows that the within-patient
overestimation is also highly variable.
Serial measurement of C1 to monitor GFR during months-
to-years of treatment is not a practical alternative in clinical
practice, because the procedure is complex, labor-intensive,
time-consuming, and expensive. Since creatinine clearance is
much easier and less expensive to measure, we sought to
determine whether the reliability of this index could be im-
proved. The possibility remained that the discrepancy in each
patient was constant over time. Even if the discrepancy ratio
were not constant, it might be possible, using other laboratory
indices, to provide a "correction factor" so that the GFR could
be reliably predicted during the patient's course using the
2.1 1.4 1.3 1.5
24 C
1.6 1.3 1.7 2.1
I • I • I
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Study number
Fig. 5. Individual patient example demonstrating the discrepancy be-
tween creatinine clearance (inpatient, C, or 24-hour outpatient, 24 hr
C) and inulin clearance over time. Symbols are: () 24-hr Ccr; (U)
Ccr; (•) C1,,.
creatinine clearance. The present study answers this question:
is the degree of overestimation constant over time in a given
patient? This is important for two reasons: 1) serial change in
Ccr is used to guide treatment of individual patients in many
illnesses [11] and 2) serial change in Ce,. is often used as an
outcome variable in the clinical study of various glomerulopa-
thies [5, 6].
We found substantial changes over time in the discrepancy
between Cr and C1, in many of the 25 lupus patients serially
studied a mean of 3.3 times over a three-year period (Table 1,
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Fig. 1). This variability over time occurred at both high and low
levels of C and regardless of whether C1 was increasing,
decreasing, or constant. Using multiple linear regression anal-
ysis, both the inpatient C and 24-hour outpatient creatinine
clearance (24 Car) were poor predictors of C1,, (Table 2) with
standard deviations of percent difference of 0.19 and 0.30,
respectively.
The variability in the discrepancy ratio, C,IJCI,,, is not
predictable. The discrepancy ratio is different in each patient
and in many patients (Table I, Fig. 1) will change dramatically
over time. Knowledge of a patient's past discrepancy ratio did
not allow a better prediction of C1,, using Ce,.(the simultaneous
in-patient creatinine clearance) or 24 Ce,. (the 24-hour out-
patient creatinine clearance; Table 2). Indeed, using the past
discrepancy ratio to predict C1,, resulted in errors as large as 30
to 40 mI/mm in both directions of over- and under-estimation of
C1, in a given patient (Fig. 2).
To further examine this same issue, we asked how often
serial Ce,. would be directionally discordant to serial C1,, (Fig.
4). In nearly one-half of all serial measurements of Car, the
corresponding changes in Ci,, were directionally discordant. In
the studies in which Ci,, changed by 10 mI/mm or more, the
direction of change was not correctly identified by the CCr
(32%), the 24 Ce,. (45%), or serum creatinine (59%), making
these measures clinically unacceptable as tests of GFR.
The discrepancy between Cr and Ci,, is due in large part to
the tubular secretion of creatinine [2, 12]. Our finding that the
discrepancy ratio changes over time in lupus patients suggests
that some clinical factor plays a role in tubular secretion.
Surprisingly, our analysis found no association between our
lupus activity index and the discrepancy ratio. However, both
prednisone use (also included as part of the lupus activity index;
P 0.02) and diuretic use (P = 0.04) were associated with the
discrepancy ratio. Only one of our patients took cimetidine, a
drug which can partially reverse the discrepancy between Ce,.
and C1,, [2, 13]. However, the degree to which the discrepancy
can be accounted for by commonly available clinical variables
is limited. For example, one patient on high and varying doses
of prednisone exhibited no discrepancy.
Previous serial studies in diverse glomerulopathies have been
limited in scope, with small numbers of patients [14] or patients
studied only at two points of time [2, 4]. Hood et al reported
serial studies on two lupus patients with CIC1,, varying from
1.80 to 3.82 in one and 1.15 to 1.66 in the second [14]. Kim et al
found, in direct contrast to our results, that serial creatinine
clearances paralleled the direction of change of the inulin
clearances in 31 patients with renal disease. Twenty of their
patients had only two studies [4]. Shemesh et a! studied 28
patients with diverse renal diseases twice over a period of 3 to
12 months. Because their results were analyzed in terms of
increasing or decreasing proteinuria, we cannot directly com-
pare our results [2]. However, our analysis (Table 2) shows that
the addition of information on proteinuria only slightly im-
proves creatinine clearance as a predictor of inulin clearance.
Our results, in a well-defined group of patients with LN, point
out for the first time the extent to which serial Ce,. and 24 CCr
will give misleading information regarding the trend in C1,, in
lupus nephropathy.
Clinicians require an accurate measure of GFR, first, to
follow the effect of therapy of lupus nephropathy, and second,
to determine the absolute level of renal dysfunction. Reliance
on the urine sediment, CH5O, and anti-DNA is not sufficient to
guide treatment, because these tests do not reflect renal func-
tion, and because patients can have significant glomerular
involvement with normal urine sediments and serologies [15].
We have not shown that more accurate knowledge of the trend
in GFR will improve treatment. However, the high degree of
inter- and intra-patient variability in the estimation of GFR by
creatinine clearance documented by this study has undoubtably
contributed greatly to the probability of Type II error in past
lupus treatment studies that relied upon serum creatinine levels
or creatinine clearances as a treatment outcome variable [5, 6].
Because 50% of lupus patients may have renal involvement [16]
and given the serious side-effects of both corticosteroids and
immunosuppressive agents, treatment decisions based solely or
in large part on serial inverse creatinine levels or creatinine
clearances must now be questioned.
We found that both C10 and CDTPA are acceptable alterna-
tives to C1,, (Fig. 3). Both C5,, [17] and CDTPA [18] are available
as outpatient techniques, using a single subcutaneous injection
with determination of renal clearances for several urine periods.
The fluorescent excitation technique for iothalamate measure-
ment, used in this study [10], obviates the need for radioactive
tracer, making frequent studies more attractive in women of
childbearing age. We recommend that, unless a way is found to
reliably "correct" the creatinine clearance, that one of these
alternative measures of GFR be utilized routinely in future
studies of lupus nephropathy.
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